Dentsply Sirona (XRAY) appooints new board members
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Canaccord Genuity Reiterates Buy Rating on Globus Medical (GMED)
February 6, 2025 1:25 PM ESTCanaccord Genuity analyst William J. Plovanic reiterated a Buy rating and $101.00 price target on Globus Medical (NYSE: GMED).
The analyst comments "Our take: We believe that this acquisition is further evidence of GMED continuing to go on the offensive even as it integrates its sizable acquisition of NUVA. With over one year since the NUVA merger, we are impressed by the progress GMED has achieved and how it's remained... More
Needham Reiterates Hold Rating on Globus Medical (GMED)
February 6, 2025 12:43 PM ESTNeedham analyst Mike Matson reiterated a Hold rating on Globus Medical (NYSE: GMED).
The analyst comments "This morning, GMED announced an agreement to acquire Nevro (NVRO, Not Rated) for $5.85 per share in cash, or an enterprise value of ~$195M. NVRO provides the HFX... More
Jefferies Reiterates Buy Rating on Globus Medical (GMED)
February 6, 2025 12:19 PM ESTJefferies analyst Matthew Taylor reiterated a Buy rating and $105.00 price target on Globus Medical (NYSE: GMED)
The analyst comments "On 2.6.25, GMED announced plans to acquire NVRO (UNPF) for ~$250MM in equity value ~0.6x sales. Assuming a 2Q25 close, GMED forecasts ~20c in... More
BTIG on Globus Medical (GMED) Buying NVRO: 'The Market May Not Like It'
February 6, 2025 11:32 AM ESTBTIG analyst Ryan Zimmerman reiterated a Buy rating and $91.00 price target on Globus Medical (NYSE: GMED).
The analyst comments "This morning, GMED announced a definitive agreement to acquire Nevro Corp (NVRO, Not Rated) for ~$250M or ~0.6x EV/FY25 sales. Yes, this is surprising on the surface. We don't believe investors expected that GMED would move into... More
